Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean category antidepressive agent an group approved?
Displaying drugs 426 - 450 of 10443 in total

Moxidectin

Moxidectin is a potent, broad-spectrum endectocide (antiparasitic that is active against endo- and ecto-parasites) with activity against nematodes, insects, and acari. It was first used in cattle followed by an approved use in general animals. It is a semi-synthetic methoxine derivative of nemadectin which is a 16-member pentacyclic lactone of...
Approved
Investigational
Vet approved
Matched Description: … It was first used in cattle followed by an approved use in general animals. ... [A33385] Moxidectin was developed by Medicines Development for Global Health and FDA approved in June …
Matched Categories: … Antinematodal Agents ... Anti-Infective Agents ... Antiparasitic Agents …

Atezolizumab

Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.[A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted...
Approved
Investigational
Matched Description: … voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved …
Matched Categories: … Antineoplastic Agents ... Antineoplastic Agents, Immunological ... Antineoplastic and Immunomodulating Agents …

Plasminogen

Plasminogen is a pro-enzyme (i.e. a zymogen) which is cleaved to form plasmin - also known as fibrinolysin - as part of the fibrinolytic pathway that breaks down fibrin blood clots. This pathway is activated when a clot is no longer needed or to prevent a clot from extending beyond...
Approved
Matched Description: … to form on the mucous membranes of patients, providing an unmet medical need for patients with this ... [L34635] In June 2021, the FDA approved a plasma-derived plasminogen (Ryplazim, human plasminogen-tvmh ... [L34615] It is the first and only FDA-approved treatment for this condition, which causes wood-like lesions …
Matched Categories: … Hematologic Agents ... Fibrinolytic Agents ... Cardiovascular Agents ... Fibrin Modulating Agents …

Ezogabine

Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy....
Approved
Investigational
Matched Description: … FDA approved in June 10, 2011 under the name of ezogabine. ... developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an …
Matched Categories: … QTc Prolonging Agents ... Central Nervous System Agents ... Potential QTc-Prolonging Agents …

Colchicine

Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as Colchicum autumnale, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events....
Approved
Matched Description: … [A183611] Its use was first approved by the FDA in 1961. ... Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum …
Matched Categories: … Antimitotic Agents ... Agents Causing Muscle Toxicity …

Daridorexant

Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia. Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of daytime functioning. It chronically affects the person's daily functioning and long-term health effects, as insomnia is often associated with comorbidities...
Approved
Matched Description: … Daridorexant was designed via an intensive drug discovery program to improve the potency and maximize ... attention after discovering the role of orexin signalling pathway in wakefulness and [almorexant], an ... [A244225] It was approved by the FDA on January 10, 2022, under the name QUVIVIQ. …
Matched Categories: … Wakefulness-Promoting Agents …

Rimegepant

Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several parenteral antagonists...
Approved
Investigational
Matched Description: … Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. ... [L41640] While several parenteral antagonists of CGRP and its receptor have been approved for migraine ... approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved …

Ropivacaine

Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
Approved
Matched Description: … Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin …
Matched Categories: … Hypotensive Agents ... Sensory System Agents ... Central Nervous System Agents ... Peripheral Nervous System Agents ... Methemoglobinemia Associated Agents …

Sulfathiazole

Sulfathiazole is a short-acting sulfa drug. It used to be a common oral and topical antimicrobial until less toxic alternatives were discovered. It is still occasionally used, sometimes in combination with sulfabenzamide and sulfacetamide. Except for those formulated for vaginal use, the FDA withdrew its approval for the use of...
Approved
Vet approved
Withdrawn
Matched Categories: … Anti-Infective Agents …

Cefradine

A semi-synthetic cephalosporin antibiotic.
Approved
Matched Categories: … Anti-Bacterial Agents ... Anti-Infective Agents ... Nephrotoxic agents …

Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) antigen (propiolactone inactivated)

A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence...
Approved
Matched Description: … from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an …

Flunisolide

Flunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid with anti-inflammatory actions. It is often prescribed as treatment for allergic rhinitis and its principle mechanism of action involves activation of glucocorticoid receptors.
Approved
Investigational
Matched Categories: … Anti-Asthmatic Agents ... Anti-Inflammatory Agents ... Agents to Treat Airway Disease ... Immunosuppressive Agents ... Respiratory System Agents …

Macimorelin

Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels...
Approved
Investigational
Matched Description: … More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an ... Growth hormone secretagogues (GHS) represent a new class of pharmacological agents which have the potential ... Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market …
Matched Categories: … Diagnostic Agents ... QTc Prolonging Agents ... Highest Risk QTc-Prolonging Agents …

Dalfampridine

Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Approved
Matched Description: … FDA approved on January 22, 2010. ... This is the first drug that was specifically approved to help with mobility in these patients. …
Matched Categories: … Cardiovascular Agents ... Other Miscellaneous Therapeutic Agents …

Ixabepilone

Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is...
Approved
Investigational
Matched Description: … Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. ... It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally …
Matched Categories: … Anti-Bacterial Agents ... Antineoplastic Agents ... Myelosuppressive Agents ... Immunosuppressive Agents ... Antineoplastic and Immunomodulating Agents …

Ecamsule

Ecamsule is an organic compound which is added to many sunscreens to filter out UVA rays. It is a benzylidene camphor derivative, many of which are known for their excellent photostability. Ecamsule has been approved for use in the U.S. since 2006, but only at a specific concentration and only...
Approved
Matched Description: … Ecamsule is an organic compound which is added to many sunscreens to filter out UVA rays. ... Ecamsule has been approved for use in the U.S. since 2006, but only at a specific concentration and only …
Matched Categories: … Sunscreen Agents ... Protective Agents ... Radiation-Protective Agents …

Sotalol

Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening...
Approved
Matched International brands: … Xi An Lin …
Matched Description: … [A178579] Sotalol was first approved as an oral tablet on 30 October 1992. …
Matched Categories: … Adrenergic Agents ... Autonomic Agents ... Antiarrhythmic agents ... Hypotensive Agents ... Cardiovascular Agents …

Adalimumab

Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor.[A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced...
Approved
Experimental
Matched Description: … - which was approved in August 2022 -,[L42935] and adalimumab-aacf - which was approved in October 2023 ... [L44953] Adalimumab-adaz was approved by the FDA on October 31, 2018. ... Adalimumab-atto was the first adalimumab biosimilar approved by the FDA in 2016. …
Matched Categories: … Antirheumatic Agents ... Anti-Inflammatory Agents ... Agents reducing cytokine levels ... Immunosuppressive Agents ... Disease-modifying Antirheumatic Agents …

Ivosidenib

Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA...
Approved
Investigational
Matched Description: … IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth ... [L46287] It was fully approved by the EMA in May 2023.[L46596] ... [A248745] It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults …
Matched Categories: … Antineoplastic Agents ... QTc Prolonging Agents ... Antineoplastic and Immunomodulating Agents ... Moderate Risk QTc-Prolonging Agents …

Zoledronic acid

Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone.[L13712,L13715,L13721] Zoledronic acid...
Approved
Matched Categories: … Bone Density Conservation Agents …

Pholcodine

Pholcodine formula is 3-o-morpholinoethylmorphine and it is classified as an antitussive which is defined as an opioid cough suppressant. It belongs to the opioid family of compounds and it is widely used. Pholcodine activity is the suppression of unproductive cough and it also has a mild sedative effect with little...
Approved
Illicit
Matched Description: … Pholcodine is not approved in Canada. ... as an opioid cough suppressant. ... Pholcodine formula is 3-o-morpholinoethylmorphine and it is classified as an antitussive which is defined …
Matched Categories: … Antitussive Agents ... Sensory System Agents ... Central Nervous System Agents ... Respiratory System Agents ... Peripheral Nervous System Agents …

Technetium Tc-99m nofetumomab merpentan

Technetium Tc-99m nofetumomab merpentan (Tc-99m nm) consists of a Fab fragment of an IgG2b of the pancarcinoma murine antibody NR-LU-10. The NR-LU-10 antibody is directed against a 40 kDa glycoprotein antigen expressed in a variety of cancers and some normal tissues.[FDA label] Tc-99m nm was developed by Boehringer Ingelheim Pharma...
Approved
Withdrawn
Matched Description: … [FDA label] Tc-99m nm was developed by Boehringer Ingelheim Pharma KG and FDA approved on September 14 ... Technetium Tc-99m nofetumomab merpentan (Tc-99m nm) consists of a Fab fragment of an IgG2b of the pancarcinoma ... , but in the 2018 FDA submission list, it can be found as a substance type II (Drug substance) with an …

Turpentine

Turpentine, also known as spirit of turpentine, oil of turpentine, and wood turpentine, is a liquid extracted from live trees, mainly pine, through distillation of resin. It is used as a solvent and base material in organic synthesis reactions. Turpentine is composed of terpenes, mainly the monoterpenes alpha-pinene and beta-pinene...
Approved
Experimental

Zinc

A metallic element of atomic number 30 and atomic weight 65.38. It is a necessary trace element in the diet, forming an essential part of many enzymes, and playing an important role in protein synthesis and in cell division. Zinc deficiency is associated with anemia, short stature, hypogonadism, impaired wound...
Approved
Investigational
Matched Description: … It is a necessary trace element in the diet, forming an essential part of many enzymes, and playing an ... A newer study suggests implies that an imbalance of zinc is associated with the neuronal damage associated …
Matched Categories: … Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use …

Factor XIII (human)

Factor XIII (human) is a heat-treated, lyophilized concentrate of coagulation factor XIII, an endogenous enzyme responsible for the crosslinking of fibrin and an essential component of the coagulation cascade [FDA Label]. For people with congenital deficiency or mutation of Factor XIII, a rare bleeding disorder, exogenous replacement of this key...
Approved
Investigational
Matched Description: … Factor XIII (Human), available as the commercially available product Corifact, is approved by the Food ... Factor XIII (human) is a heat-treated, lyophilized concentrate of coagulation factor XIII, an endogenous ... enzyme responsible for the crosslinking of fibrin and an essential component of the coagulation cascade …
Displaying drugs 426 - 450 of 10443 in total